MACC1 Is Associated With Epithelial-Mesenchymal Transition and Can Predict Poor Prognosis in Nasopharyngeal Carcinoma.
E-cadherin
epithelial-mesenchymal transition (EMT)
metastasis-associated in colon cancer 1 (MACC1)
nasopharyngeal carcinoma
prognostic biomarker
vimentin
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2021
2021
Historique:
received:
20
12
2020
accepted:
11
03
2021
entrez:
15
4
2021
pubmed:
16
4
2021
medline:
16
4
2021
Statut:
epublish
Résumé
Given the reported correlation between the oncogene metastasis-associated in colon cancer 1 (MACC1) and nasopharyngeal carcinoma (NPC), as well as between MACC1 and epithelial-mesenchymal transition (EMT), we speculated that EMT is a likely causative link between MACC1 expression and poor NPC prognosis. Thus, we aim to clarify the relationship between MACC1 and EMT in NPC prognosis. We performed immunohistochemical examination of tissue sections from 128 NPC patients that were divided into six groups corresponding to high and low protein expression of MACC1 and two EMT-related proteins, vimentin and E-cadherin, and Kaplan-Meier (KM) survival analyses were performed. KM survival analysis showed that upregulation of MACC1 and vimentin and downregulation of E-cadherin were significantly associated with reduced survival in NPC. Short hairpin RNA (shRNA) interference and immunoblotting in the NPC cell line HNE-1 led to increased E-cadherin but decreased vimentin levels. MACC1 overexpression was significantly correlated with poor 5-year overall survival, metastasis-free survival, and disease-free survival (P<0.05) but not with poor relapse-free survival (P>0.05). Univariate analyses revealed that MACC1, E-cadherin, and vimentin levels along with T and N tumor classifications and cancer staging are significant prognostic factors of NPC (P<0.05). Our findings showed the association between MACC1 and EMT in NPC malignancy and support the role of MACC1 as a prognostic biomarker and molecular target for NPC treatment.
Sections du résumé
BACKGROUND
BACKGROUND
Given the reported correlation between the oncogene metastasis-associated in colon cancer 1 (MACC1) and nasopharyngeal carcinoma (NPC), as well as between MACC1 and epithelial-mesenchymal transition (EMT), we speculated that EMT is a likely causative link between MACC1 expression and poor NPC prognosis. Thus, we aim to clarify the relationship between MACC1 and EMT in NPC prognosis.
MATERIAL AND METHODS
METHODS
We performed immunohistochemical examination of tissue sections from 128 NPC patients that were divided into six groups corresponding to high and low protein expression of MACC1 and two EMT-related proteins, vimentin and E-cadherin, and Kaplan-Meier (KM) survival analyses were performed.
RESULTS
RESULTS
KM survival analysis showed that upregulation of MACC1 and vimentin and downregulation of E-cadherin were significantly associated with reduced survival in NPC. Short hairpin RNA (shRNA) interference and immunoblotting in the NPC cell line HNE-1 led to increased E-cadherin but decreased vimentin levels. MACC1 overexpression was significantly correlated with poor 5-year overall survival, metastasis-free survival, and disease-free survival (P<0.05) but not with poor relapse-free survival (P>0.05). Univariate analyses revealed that MACC1, E-cadherin, and vimentin levels along with T and N tumor classifications and cancer staging are significant prognostic factors of NPC (P<0.05).
CONCLUSION
CONCLUSIONS
Our findings showed the association between MACC1 and EMT in NPC malignancy and support the role of MACC1 as a prognostic biomarker and molecular target for NPC treatment.
Identifiants
pubmed: 33854976
doi: 10.3389/fonc.2021.644120
pmc: PMC8039464
doi:
Types de publication
Journal Article
Langues
eng
Pagination
644120Informations de copyright
Copyright © 2021 Cheng, Zhou, Long, Xiang and Chen.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Thorac Cardiovasc Surg. 2011 Apr;141(4):895-8
pubmed: 21093878
Anticancer Res. 2010 Sep;30(9):3441-4
pubmed: 20944120
Expert Opin Ther Targets. 2013 Sep;17(9):1039-52
pubmed: 23815185
Int J Cancer. 2013 Sep 15;133(6):1419-30
pubmed: 23457029
PLoS One. 2013;8(4):e60821
pubmed: 23573286
J Exp Clin Cancer Res. 2011 Sep 16;30:83
pubmed: 21923915
BMC Cancer. 2015 Mar 21;15:160
pubmed: 25884643
J Clin Oncol. 1998 Apr;16(4):1310-7
pubmed: 9552031
Biosci Trends. 2016 Sep 5;10(4):258-64
pubmed: 27488539
World J Clin Cases. 2015 May 16;3(5):393-404
pubmed: 25984514
J Mammary Gland Biol Neoplasia. 2010 Jun;15(2):117-34
pubmed: 20490631
NPJ Precis Oncol. 2017 May 15;1(1):10
pubmed: 29872698
Oncotarget. 2017 Oct 24;8(57):97323-97330
pubmed: 29228613
Oral Oncol. 2017 Sep;72:65-72
pubmed: 28797463
J Transl Med. 2011 Sep 29;9:166
pubmed: 21955323
BMC Cancer. 2012 Mar 19;12:91
pubmed: 22429801
Oncotarget. 2010 Nov;1(7):651-61
pubmed: 21317460
Nat Med. 2009 Jan;15(1):59-67
pubmed: 19098908
Radiother Oncol. 2011 Jun;99(3):392-397
pubmed: 21680037
Tumour Biol. 2015 Aug;36(8):6239-48
pubmed: 25775951
J Cancer Res Clin Oncol. 2015 Aug;141(8):1353-61
pubmed: 25544672
Nat Rev Mol Cell Biol. 2006 Feb;7(2):131-42
pubmed: 16493418
Cancer Cell Int. 2013 Dec 10;13(1):121
pubmed: 24325214
Clin Cancer Res. 2016 Aug 15;22(16):4005-13
pubmed: 27370607
Tumour Biol. 2014 Jan;35(1):815-9
pubmed: 23982875
Oncotarget. 2016 Sep 13;7(37):59144-59157
pubmed: 27463018
Int J Biochem Cell Biol. 2009 Dec;41(12):2356-9
pubmed: 19666136
Chin J Cancer. 2011 Feb;30(2):114-9
pubmed: 21272443
Clin Cancer Res. 2008 Oct 1;14(19):5941-6
pubmed: 18829470
Korean J Pathol. 2012 Aug;46(4):341-8
pubmed: 23110026
Oncotarget. 2016 Apr 5;7(14):18085-94
pubmed: 26919111
Biochim Biophys Acta. 2015 Oct;1853(10 Pt A):2453-63
pubmed: 26001768
Hepatology. 2015 Sep;62(3):841-50
pubmed: 25953673
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Exp Ther Med. 2018 Apr;15(4):3687-3692
pubmed: 29556258
Br J Cancer. 2013 Aug 6;109(3):788-94
pubmed: 23807164
Clin Cancer Res. 2013 Jan 1;19(1):3-5
pubmed: 23172883
Biomed Pharmacother. 2020 May;125:109986
pubmed: 32058221
Int J Gynecol Cancer. 2015 Oct;25(8):1353-63
pubmed: 26332389